Compositions of somatostatin analogues

1. A composition of somatostatin analogues having the general formula:

wherein:

Z may be absent or present and when present is selected from the group consisting of DOTA-based chelators, DTPA-based chelators, NOTA-based chelators, carbonyl compounds, hydrazino nicotinamide, N 4 -chelators, desferrioxamine, N X S Y -chelators, tyrosine for halogenation, a fluorescent dye and biotin;

L may or may not be present and is a linker molecule;

X1 is a symmetric or asymmetric diamino acid containing 3 or 4 consecutive C atoms;

X2 is a positively charged natural or unnatural amino acid, an arginine mimic, citrulline, or a neutral amino acid;

X3 is phenylalanine, Ala-[3-(2-thienyl)], α-naphthylalanine, or β-naphthylalanine;

X4 is an aromatic amino acid;

X5 is threonine or serine; and

X6 is phenylalanine, Ala-[3-(2-thienyl)], α-naphthylalanine or β-naphthylalanine.

2. The composition of claim 1 , wherein X2 is selected from the group consisting of diamino propionic acid and diamino butyric acid.

3. The composition of claim 1 , wherein X2 is selected from the group consisting of lysine, I-Amp, ornithine, and L/D-Phg(4-amino).

4. The composition of claim 1 , wherein X2 is the arginine mimic.

5. The composition of claim 1 , wherein X4 is selected from the group consisting of tyrosine, halogenated tyrosine, iodinated tyrosine, dimethyltyrosine, α-naphthylalanine, β-naphthylalanine, and halogenated phenylalanine.

6. The composition of claim 1 , wherein L is selected from the group consisting of tyrosine, lysine, β-alanine, sarcosine, succinic acid, and glutaric acid.

7. The composition of claim 1 , wherein Z is complexed with a radioisotope selected from the group consisting of 114m In, 186 Re, 188 Re, 77 As, 90 Y, 66 Ga, 67 Cu, 169 Er, 117m Sn, 121 Sn, 127 Te, 142 Pr, 143 Pr, 195m Pt, 198 Au, 199 Au, 149 Tb, 161 Tb, 109 Pd, 165 Dy, 149 Pm, 151 Pm, 153 Sm, 157 Gd, 159 Gd, 166 Ho, 172 Tm, 169 Yb, 175 Yb, 177 Lu, 105 Rh, 111 Ag, 123 I, 124 I, 125 I, 131 I, 203 Bi, 211 At, and 103m Rh.

8. The composition of claim 1 , wherein X2 is arginine.

9. The composition of claim 1 , wherein X3 is phenylalanine.

10. The composition of claim 1 , wherein X4 is phenylalanine.

11. The composition of claim 1 , wherein X4 is tyrosine.

12. The composition of claim 1 , wherein X5 is threonine.

13. The composition of claim 1 , wherein X6 is phenylalanine.

14. The composition of claim 1 , wherein X1 is diamino butyric acid.

15. The composition of claim 1 having the general formula:

16. The composition of claim 1 , wherein Z is DOTA.

17. The composition of claim 1 , wherein Z is DOTAGA.

18. The composition of claim 1 , wherein Z is tyrosine.

19. The composition of claim 1 , wherein L is absent.

20. The composition of claim 1 , further comprising a radioactive isotope selected from the group consisting of 99m Tc, 203 Pb, 67 Ga, 68 Ga, 72 As, 111 In, 113 In, 123 I, 177 Lu, 97 Ru, 62 Cu, 64 Cu, 52 Fe, 52m Mn, 51 Cr, 124 I and 18 F.

21. The composition of claim 1 , further contained within a pharmaceutical composition comprising a suitable excipient.

22. The composition of claim 21 , further comprising a radioactive isotope selected from the group consisting of 99m Tc, 203 Pb, 67 Ga, 68 Ga, 72 As, 111 In, 113m In, 123 I, 124 I, 18 F, 177 Lu, 97 Ru, 62 Cu, 64 Cu, 52 Fe, 52m Mn and 51 Cr.

23. The composition of claim 21 , further comprising a radioisotope selected from the group consisting of 114m In, 186 Re, 188 Re, 77 As, 90 Y, 66 Ga, 67 Cu, 169 Er, 117m Sn, 121 Sn, 127 Te, 142 Pr, 143 Pr, 198 Au, 199 Au, 149 Tb, 161 Tb, 109 Pd, 165 Dy, 149 Pm, 151 Pm, 153 Sm, 157 Gd, 159 Gd, 166 Ho, 172 Tm, 169 Yb, 175 Yb, 177 Lu, 105 Rh, 111 Ag, 124 I and 131 I.

24. The composition of claim 1 , wherein X1 is D/L-diamino butyric acid.

25. The composition of claim 1 , wherein X1 is D/L-diamino propionic acid.

26. The composition of claim 1 , wherein Z is a chelating agent selected from the group consisting of p-NH 2 -Bz-DOTA, DOTA-p-NH 2 -anilide, and MeO—NH 2 -Ph-DOTA.

27. The composition of claim 1 , wherein X2 is asparagine.

28. The composition of claim 1 , wherein X4 is a halogenated aromatic amino acid.

29. The composition of claim 4 , wherein the arginine mimic is selected from the group consisting of R/S-Gly-Ala-4-Pip(N-amidino), D/L-Phe(4-guanidino), and R/S-2-amino-4-[4-(2-amino)pyrimidinyl]butanoic acid.

30. The composition of claim 5 , wherein X4 is iodated phenylalanine.

31. The composition of claim 1 having the general formula:

32. A composition of somatostatin analogues having the general formula:

wherein:

Z may be absent or present and when present is selected from the group consisting of DOTA-based chelators, DTPA-based chelators, NOTA-based chelators, carbonyl compounds, hydrazino nicotinamide, N 4 -chelators, desferrioxamine, N X S Y -chelators, tyrosine for halogenation, a fluorescent dye, and biotin;

L may or may not be present and is a linker molecule; and

X4 is Phe or Tyr.

33. The composition of claim 32 , further comprising a radioactive isotope selected from the group consisting of 99m Tc, 203 Pb, 67 Ga, 68 Ga, 72 As, 111 In, 113 In, 123 I, 124 I, 18 F, 177 Lu, 97 Ru, 62 Cu, 64 Cu, 52 Fe, 52m Mn and 51 Cr.

34. The composition of claim 32 , further comprising a radioisotope selected from the group consisting of 114m In 186 Re, 188 Re, 77 As, 90 Y, 66 Ga, 67 Cu, 169 Er, 117m Sn, 121 Sn, 127 Te, 142 Pr, 143 Pr, 198 Au, 199 Au, 149 Tb, 161 Tb, 109 Pd, 165 Dy, 149 Pm, 151 Pm, 153 Sm, 157 Gd, 159 Gd, 166 Ho, 172 Tm, 169 Yb, 175 Yb, 177 Lu, 105 Rh, 111 Ag, 124 I, and 131 I.